Goldman Sachs Group Analysts Give MorphoSys (ETR:MOR) a €114.00 Price Target

Goldman Sachs Group set a €114.00 ($132.56) price objective on MorphoSys (ETR:MOR) in a research note published on Monday, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

Several other analysts also recently issued reports on the stock. Berenberg Bank set a €108.00 ($125.58) price objective on shares of MorphoSys and gave the stock a buy rating in a report on Tuesday, April 2nd. JPMorgan Chase & Co. set a €120.00 ($139.53) price target on shares of MorphoSys and gave the company a buy rating in a report on Wednesday, May 8th. Deutsche Bank set a €125.00 ($145.35) price target on shares of MorphoSys and gave the company a buy rating in a report on Friday, April 26th. Independent Research set a €96.00 ($111.63) price target on shares of MorphoSys and gave the company a neutral rating in a report on Thursday, March 14th. Finally, Royal Bank of Canada set a €65.00 ($75.58) price target on shares of MorphoSys and gave the company a sell rating in a report on Thursday, March 14th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average target price of €100.78 ($117.18).

ETR MOR opened at €82.80 ($96.28) on Monday. The company has a current ratio of 7.75, a quick ratio of 7.53 and a debt-to-equity ratio of 8.65. The business’s fifty day moving average price is €88.99. The company has a market cap of $2.61 billion and a P/E ratio of -44.56. MorphoSys has a 1 year low of €76.45 ($88.90) and a 1 year high of €124.90 ($145.23).

About MorphoSys

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Recommended Story: Why do companies pay special dividends?

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.